# Evaluate the Safety and Pharmacokinetics/Pharmacodynamics and Food Effect of HS-20118

> **NCT07033234** · PHASE1 · RECRUITING · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 142 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** HS-20118

## Key facts

- **NCT ID:** NCT07033234
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-16
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 142 (ESTIMATED)
- **Last updated:** 2025-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07033234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07033234, "Evaluate the Safety and Pharmacokinetics/Pharmacodynamics and Food Effect of HS-20118". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07033234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*